Relmada Therapeutics (RLMD) Tops Q3 EPS by 18c

Relmada Therapeutics (NASDAQ: RLMD) reported Q3 EPS of ($0.73), $0.18 better than the analyst estimate of ($0.91).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
• Hermès can regain momentum despite China weakness, Jefferies says